Keywords: guidant, acquire, biosensors, everolimus-eluting, stent, corp, entered
Guidant to acquire Biosensors' everolimus-eluting stent
Article | 31 March 2003
Guidant Corp has entered into a definitive agreement to acquire certainassets of Biosensors International's everolimus-eluting stent program. The agreement provides ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
